Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00573391 · ClinicalTrials.gov registry record · Phase 3
Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2
A Phase 3 study, sponsored by University of Arkansas.
- Terminated
- Registry status
- Phase 3
- Development phase
- 5
- Enrollment target
NCT00573391 is a Phase 3 study that was terminated before completion, run by University of Arkansas. The registered enrollment target is 5 participants.
The verdict
NCT00573391, a Phase 3 study, was terminated before completion, sponsored by University of Arkansas.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study is being done to find out if the combination of VelcadeTM with melphalan and dexamethasone (VMD) will be as effective, or even more effective as it is in combination with thalidomide and dexamethasone (VTD).
Interventions
- DRUG Velcade, Thalidomide, and Dexamethasone
- DRUG Velcade, Melphalan, and Dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2006-08 |
| Est. Completion | 2008-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00573391
The ClinicalTrials.gov registry entry for NCT00573391 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Velcade, Thalidomide, and Dexamethasone is the first listed.
NCT00573391 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00573391 about?
NCT00573391 is a clinical study titled "Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2". This study is being done to find out if the combination of VelcadeTM with melphalan and dexamethasone (VMD) will be as effective, or even more effective as it is in combination with thalidomide and dexamethasone (VTD).
What is the current status of trial NCT00573391?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 5 participants. The study started on 2006-08. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00573391?
The interventions under investigation include: Velcade, Thalidomide, and Dexamethasone (DRUG), Velcade, Melphalan, and Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT00573391?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.